Vaxcyte, Inc.

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-02-10 pm EST			5-day change	1st Jan Change
85.94 ^USD	-1.69%		+1.33%	+4.98%

Feb. 07	Vaxcyte Insider Sold Shares Worth $450,369, According to a Recent SEC Filing	MT
Feb. 05	Vaxcyte Advances Phase 2 Study on Infant Pneumococcal Disease Prevention to Final Stage	MT

Vaxcyte Insider Sold Shares Worth $6,283,861, According to a Recent SEC Filing

October 03, 2024 at 04:33 pm EDT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Vaxcyte, Inc.

Vaxcyte Insider Sold Shares Worth $450,369, According to a Recent SEC Filing	Feb. 07	MT
Vaxcyte Advances Phase 2 Study on Infant Pneumococcal Disease Prevention to Final Stage	Feb. 05	MT
Vaxcyte, Inc. Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for Prevention of Invasive Pneumococcal Disease in Infants	Feb. 05	CI
Vaxcyte Insider Sold Shares Worth $427,923, According to a Recent SEC Filing	Jan. 07	MT
Vaxcyte Insider Sold Shares Worth $710,249, According to a Recent SEC Filing	Dec. 19	MT
Vaxcyte, Inc. Initiates Phase 2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Infants	Dec. 03	CI
Vaxcyte, Inc. Announces Amended and Restated the Original Lease and Enters into Sublease Agreement with Iovance Biotherapeutics, Inc	Nov. 21	CI
Vaxcyte Insider Sold Shares Worth $686,518, According to a Recent SEC Filing	Nov. 19	MT
Vaxcyte, Inc. Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs	Nov. 12	CI
Vaxcyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 05	CI
Certain Restricted Stock Units of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 4-NOV-2024.	Nov. 03	CI
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 4-NOV-2024.	Nov. 03	CI
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 4-NOV-2024.	Nov. 03	CI
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 4-NOV-2024.	Nov. 03	CI
Vaxcyte Insider Sold Shares Worth $4,846,508, According to a Recent SEC Filing	24-10-22	MT
Vaxcyte Insider Sold Shares Worth $6,283,861, According to a Recent SEC Filing	24-10-03	MT
Vaxcyte Insider Sold Shares Worth $927,551, According to SEC Filing	24-09-19	MT
Vaxcyte Insider Sold Shares Worth $1,159,635, According to a Recent SEC Filing	24-09-18	MT
Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...	24-09-10
Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	24-09-10	MT
Health Care Helped By Defensive Bias - Health Care Roundup	24-09-06	DJ
Vaxcyte Closes $1.5 Billion Offering of Shares, Warrants	24-09-06	MT
Vaxcyte Prices $1.3 Billion Offering of Shares, Warrants	24-09-05	MT
Health Care Losses Limited By Vaxcyte's Surge - Health Care Roundup	24-09-03	DJ
Vaxcyte Starts $1 Billion Underwritten Public Offering	24-09-03	MT

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Employees

254

Sector

Biotechnology & Medical Research

Calendar

2025-03-02 - Q4 2024 Earnings Release (Projected)

More about the company